Table 1.
Clinical characteristics of enrolled patients.
| Indicators | Group 1 (n = 111) | Group 2 (n = 47) | p-Value |
|---|---|---|---|
| Male, n (%) | 91 (82.0) | 40 (84.4) | 0.8 |
| Age, years | 62.0 (56.0; 66.0) | 65.0 (61.0; 70.0) * | 0.008 |
| Smokers, n (%) | 75 (67.6) | 33 (70.2) | 0.74 |
| Body mass index > 30, n (%) | 53 (47.7) | 21 (44.7) | 0.72 |
| History of myocardial infarction, n (%) | 71 (64.0) | 30 (63.8) | 0.99 |
| History of CAD, months | 15.5 (8.0; 72.0) | 60.0 (13.5; 138.0) * | 0.01 |
| Hypertension, n (%) | 110 (99.1) | 47 (100.0) | 0.66 |
| Diabetes mellitus, n (%) | 17 (15.3) | 10 (21.3) | 0.36 |
| Transient ischemic attack/stroke, n (%) | 9 (8.1) | 4 (8.5) | 0.58 |
| Peripheral artery disease, n (%) | 110 (99.0) | 46 (98.0) | 0.88 |
| COPD, n (%) | 86 (77.5) | 39 (83.0) | 0.57 |
| Chronic kidney disease, n (%) | 14 (12.6) | 5 (10.6) | 0.8 |
| Medical treatment before surgery: | |||
| β blockers, n (%) | 89 (80.2) | 38 (81.3) | 0.9 |
| angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, n (%) | 78 (70.3) | 34 (72.3) | 0.79 |
| calcium channel blockers, n (%) | 33 (29.7) | 15 (31.9) | 0.78 |
| nitrates, n (%) | 49 (44.1) | 25 (53.2) | 0.3 |
| diuretics, n (%) | 12 (10.8) | 6 (12.8) | 0.86 |
| atorvastatin, n (%) | 63 (56.8) | 19 (40.4) | 0.06 |
| aspirin, n (%) | 92 (83.0) | 34 (72.3) | 0.13 |
| clopidogrel, n (%) | 47 (42.3) | 16 (34.0) | 0.33 |
NYHA—New York Heart Association. *—p < 0.05